Drug Trial Radar · NCT05934253
The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jul 15, 2023
Primary completion
Jan 15, 2024
Study completion Feb 15, 2024
Sponsor
- Lead sponsor
- Harrow IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate if Iheezo's (chloroprocaine 3%) gel vehicle acts as a barrier on the ocular surface, potentially blocking the bactericidal action of povidone-iodine.
Conditions
- Antiseptic
- Anesthesia, Local
Interventions
Chloroprocaine ophthalmic gel 3%Drug
FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in colony forming unitsTime frame: Baseline and 5 minutes after baseline.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brandon Eye Associates
Brandon, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.